You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • SAT0396 Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from A Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing (Measure 2)

Article metrics

Article menu
Download PDFPDF
Poster Presentations
Spondyloarthritis - treatment
SAT0396 Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from A Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing (Measure 2)

 

Online download statistics by month:

Online download statistics by month: July 2016 to March 2024

AbstractFullPdf
Jul 2016301
Aug 20161502
Sep 20161603
Oct 2016700
Nov 20162300
Dec 201631041
Jan 201732044
Feb 20172205
Mar 20173906
Apr 20171507
May 20171605
Jun 201724015
Jul 20173002
Aug 20175008
Sep 201724010
Oct 201742010
Nov 20173006
Dec 20173600
Jan 20181000
Feb 20181402
Mar 20181400
Apr 20181401
May 20182000
Jun 20182800
Jul 20182401
Aug 20184400
Sep 20181401
Oct 20182601
Nov 20182402
Dec 20181000
Jan 2019600
Feb 20191600
Mar 2019401
Apr 20192401
May 2019601
Jul 2019500
Aug 2019400
Sep 20193001
Oct 20191201
Nov 20191000
Dec 2019600
Jan 2020200
Feb 20201000
Apr 20203200
May 20201000
Jun 2020600
Jul 2020800
Aug 20201600
Sep 20203200
Oct 20201802
Nov 20201000
Dec 2020200
Jan 20211201
Feb 2021200
Mar 2021800
Oct 20211000
Nov 2021800
Dec 2021600
Feb 2022600
Mar 2022400
Apr 2022903
May 20221301
Jun 20221200
Jul 20221800
Aug 2022600
Sep 20221100
Oct 20221200
Nov 2022600
Dec 20221000
Jan 2023801
Feb 2023400
Mar 2023800
Apr 2023200
May 20231400
Jun 2023800
Jul 2023200
Aug 2023200
Sep 20232600
Dec 2023600
Jan 20241300
Feb 2024200
Mar 20241000
Total12240186